Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024 2028

Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024 2028

Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases

RELEASE DATE
19-Jun-2024
REGION
Global
Deliverable Type
Technology Research
Research Code: DAED-01-00-00-00
SKU: HC_2024_802
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC_2024_802

Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024 2028
Published on: 19-Jun-2024 | SKU: HC_2024_802

Need more details?
$4,950.00
DownloadLink
Need more details?

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early progression cannot be detected by the structural or functional changes associated with NDDs.

This study is a comprehensive analysis that explores technological advancements, industry dynamics, strategic insights, and growth opportunities in molecular diagnostics for NDDs. It captures the role of leading companies, growing start-ups, and smaller companies with innovative product portfolios and an industry presence, key drivers and restraints, and strategic partnerships. The study also delves into funding, grants, mergers and acquisitions (M&As), and commercialization efforts.

Overall, this study aims to provide insights into the evolving landscape of molecular diagnostics for NDDs and implications for healthcare innovation and patient care.

Key Questions the Study Answers:
1. What are the different molecular diagnostics for NDDs?
2. What are the main challenges and complexities in the widespread adoption of molecular diagnostics compared to imaging diagnostics?
3. What are the primary sources of biomarkers used in NDDs? Who are the key and emerging participants in terms of innovation and technology in this space?
4. How are omics technologies, smart PoC devices, and exosome-mediated diagnoses emerging as novel molecular diagnostics modalities for NDDs? How do they improve accuracy?
5. What are the strategic implications of the emerging collaborations and M&As between academia and industry participants?
6. How do patents contribute to advancements in diagnostics and therapeutics for NDDs?
7. What are the growth opportunities for molecular diagnostics for NDDs?

Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Molecular Diagnostics for the Neurodegenerative Diseases Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Dementia Disease Burden Forecast for 2050

Insights into NDD Research: Trends in Publications and Clinical Trials, 2019–2024

NDDs: Overview and Importance of Early Diagnosis

Segmentation

Challenges in Early NDD Diagnosis

Diagnostic Modalities in the NDD Landscape

Sources of NDD Molecular Biomarkers

Scope of Analysis

NDD Diagnosis: Biomarker Sources, Sample Extraction, and Analytes

Biomarker Sources: A Comparative Analysis

Biomarker Sources: A Comparative Analysis (continued)

Integrated Landscape of NDD Biomarkers

Growth Drivers

Growth Restraints

CSF-based Molecular Diagnostics to Detect NDDs

Key Companies Developing CSF-based Molecular Diagnostics for NDDs

Key Companies Developing CSF-based Molecular Diagnostics for NDDs (continued)

Key Biomarkers for Neurodiagnostics: CSF-based Biomarkers, Global, 2024

Blood-based Biomarkers in NDD Diagnosis

Key Companies Developing Blood-based Molecular Diagnostics for NDDs

Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs

Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs (continued)

Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs (continued)

Key Biomarkers for Neurodiagnostics: Blood-based Biomarkers, Global, 2024

Salivary Biomarkers: An Accessible and Painless Diagnostic Approach for NDDs

Emerging Companies Developing Saliva-based Molecular Diagnostics for NDDs

Urinary Biomarkers for Early Diagnosis of NDDs

Emerging Companies Developing Urine-based Molecular Diagnostics for NDDs

Ocular Biomarkers: A New Frontier in NDD Diagnosis

Neurobiomarkers: Molecular Alterations in the Ocular Space

Emerging Companies Developing Ocular-based Molecular Diagnostics for NDDs

Emerging Companies Developing Ocular-based Molecular Diagnostics for NDDs (continued)

Skin-based Biomarkers for NDDs

Key Insights: Biomarker Utilization by Industry Participants in the NDD Diagnostics Space

Molecular Biomarkers: From Bench to Clinic, Impact Analysis

Notable Clinical Trials in NDD Molecular Diagnostics

European Platform for Neurodegenerative Disorders (EPND): A Collaborative Approach to Data and Sample Sharing

Databases and Biobanks: Catalysts for Biomarker Discovery in NDD Diagnosis

Epigenetic Alterations as NDD Biomarkers

Big Data-powered Multiomics for NDD Diagnosis

Exosomes: A Potential Candidate for Early NDD Diagnosis

Portable Molecular Diagnostic Devices Enabling Smart Diagnostics for NDDs

Synaps Dx, US

AgenT Biotech, France

Urvogelbio, India

Resonant, US

Neurodex, US

Notable NDD Diagnostics Collaborations and Clinical Alliances

Notable NDD Diagnostics Collaborations and Clinical Alliances (continued)

Notable NDD Diagnostics Collaborations and Clinical Alliances (continued)

Recent NDD Diagnostics Mergers and Acquisitions

Global Companies in NDD Diagnostics: Insight into Regional Adoption

Snapshot of Public Funding for Molecular Diagnostics of NDDs in the US, 2019–2024

Special Focus on NIH Funding for Molecular Diagnostics of AD, 2019–2024

EU R&D Projects, 2019–2023

EU R&D Projects, 2019–2023 (continued)

Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2021–2024

Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2020–2023

IP Trends in the Molecular Neurobiomarker Industry, 2019–2024

Patents by Key Participants in the NDD Diagnostics Space, 2019–2024

Analysis of IP Trends in the Molecular Neurobiomarker Industry, 2019–2024

Molecular Diagnostics in NDDs: Technology, Innovation, and Application Impact Analysis

Commercial Availability of Different Molecular Diagnostic Technologies in the NDD Landscape

Molecular Diagnosis of NDDs: A Technology Road Map

Growth Opportunity 1: Smart Diagnostics at the Point of Care for NDD Detection and Management

Growth Opportunity 1: Smart Diagnostics at the Point of Care for NDD Detection and Management (continued)

Growth Opportunity 2: Integrated Diagnostics for Comprehensive NDD Assessment

Growth Opportunity 2: Integrated Diagnostics for Comprehensive NDD Assessment (continued)

Growth Opportunity 3: Exosomics and Metabolomics in the NDD Space

Growth Opportunity 3: Exosomics and Metabolomics in the NDD Space (continued)

Technology Readiness Levels (TRLs): Explanation

Benefits and Impacts of Growth Opportunities

Next Steps

Take the Next Step

Legal Disclaimer

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early progression cannot be detected by the structural or functional changes associated with NDDs. This study is a comprehensive analysis that explores technological advancements, industry dynamics, strategic insights, and growth opportunities in molecular diagnostics for NDDs. It captures the role of leading companies, growing start-ups, and smaller companies with innovative product portfolios and an industry presence, key drivers and restraints, and strategic partnerships. The study also delves into funding, grants, mergers and acquisitions (M&As), and commercialization efforts. Overall, this study aims to provide insights into the evolving landscape of molecular diagnostics for NDDs and implications for healthcare innovation and patient care. Key Questions the Study Answers: 1. What are the different molecular diagnostics for NDDs? 2. What are the main challenges and complexities in the widespread adoption of molecular diagnostics compared to imaging diagnostics? 3. What are the primary sources of biomarkers used in NDDs? Who are the key and emerging participants in terms of innovation and technology in this space? 4. How are omics technologies, smart PoC devices, and exosome-mediated diagnoses emerging as novel molecular diagnostics modalities for NDDs? How do they improve accuracy? 5. What are the strategic implications of the emerging collaborations and M&As between academia and industry participants? 6. How do patents contribute to advancements in diagnostics and therapeutics for NDDs? 7. What are the growth opportunities for molecular diagnostics for NDDs?
More Information
Deliverable Type Technology Research
Author Isai Pratha Karthik
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Molecular Diagnostics
Keyword 2 Neurodegenerative Diseases
Keyword 3 Neurodegenerative Diagnostics
Podcast No
WIP Number DAED-01-00-00-00